ReviewFrontiers in medicine2018
The Genetics of Pemphigus Vulgaris.
Review in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Association of four CTLA-4 gene polymorphisms with pemphigus risk: a systematic review, meta-analysis, and meta-regression.The Journal of international medical research · 2024Pooled it
- What protein kinases are crucial for acantholysis and blister formation in pemphigus vulgaris? A systematic review.Journal of cellular physiology · 2022Pooled it
- Autoimmune Oral Mucosal Diseases in Older Patients: An Overview of Early Recognition and Management in the Primary Care Setting.Geriatrics (Basel, Switzerland) · 2026Review
- Genetic variations in theDermatology reports · 2025Article
- The association between aromatic amino acids consumption and the severity of pemphigus vulgaris: a cross-sectional study.Scientific reports · 2025Article
- Integration of Longitudinal Clinical, Immunologic, and Environmental Data for Enhanced Disease Monitoring and Management in Pemphigus Vulgaris: A Case Study.JID innovations : skin science from molecules to population health · 2025Article
- Autoimmune pemphigus: difficulties in diagnosis and the molecular mechanisms underlying the disease.Frontiers in immunology · 2025Review
- Clinical Characteristics, Comorbidities, and Treatment in Patients with Pemphigus-A Single-Center Retrospective Study.Antibodies (Basel, Switzerland) · 2024Article
- High dietary acid load predicts severity of autoimmune skin disease: a cross-sectional study.Scientific reports · 2024Article
- AssessingJournal of medicine and life · 2024Article
- Exploring the depths of IgG4: insights into autoimmunity and novel treatments.Frontiers in immunology · 2024Review
- Role of Human Leukocyte Antigen Class II in Antibody-Mediated Skin Disorders.Medicina (Kaunas, Lithuania) · 2023Review
- Coexistence of malignancies in pemphigus vulgaris.Immunologic research · 2023Article
- Association of alternative healthy eating index and severity of pemphigus vulgaris: A cross-sectional study.PloS one · 2023Article
- HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment.Frontiers in medicine · 2023Article
- HLA class II antigens in Croatian patients with pemphigus vulgaris and their correlation with anti-desmoglein antibodies.Frontiers in immunology · 2023Article
- Mouse models of pemphigus: valuable tools to investigate pathomechanisms and novel therapeutic interventions.Frontiers in immunology · 2023Review
- Understanding CD4Frontiers in immunology · 2023Review
- Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris.JAAD case reports · 2023Article
- De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV.Dermatologic therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pemphigus vulgaris (PV) is a severe autoimmune blistering disease caused by auto-antibodies (auto-Abs) directed against epithelial desmosomal components and leading to disruption of cell-cell adhesion. The exact mechanisms underlying the disease pathogenesis remain unknown and treatment is still based on immunosuppressive drugs, such as corticosteroids, which are associated with potentially significant side effects. Ethnic susceptibility, familial occurrence, and autoimmune comorbidity, suggest a genetic component to the pathogenesis of the disease, which, if discovered, could advance our understanding of PV pathogenesis and thereby point to novel therapeutic targets for this life-threatening disorder. In this article, we review the evidence for a genetic basis of PV, summarize the different approaches used to investigate susceptibility traits for the disease and describe past and recent discoveries regarding genes associated with PV, most of which belong to the human leukocyte antigen (HLA) locus with limited data regarding association of non-HLA genes with the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.